Personalis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 102 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Personalis Inc is 7.29, ranking 127 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 14.49M, representing a year-over-year decrease of 43.62%, while its net profit experienced a year-over-year decrease of 44.61%.
Key Metrics
The current valuation score of Personalis Inc is 6.10, ranking 330 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.62, which is -95.95% below the recent high of -0.39 and -39.66% above the recent low of -13.43.
The current earnings forecast score of Personalis Inc is 8.29, ranking 137 out of 392 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 12.00 and a low of 10.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Personalis Inc is 6.99, ranking 124 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.61 and the support level at 6.38, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Personalis Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 67.82%, representing a quarter-over-quarter increase of 27.51%. The largest institutional shareholder is Catherine Wood, holding a total of 7.91M shares, representing 8.91% of shares outstanding, with 9.45% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Personalis Inc is 3.14, ranking 169 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Personalis Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
